Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main focus: Gene editing for the treatment of genetic diseases

Company stage: Clinical

Diseases: Beta-thalassemia, other undisclosed anaemias, lymphoma, solid tumours, neuromuscular diseases, Hurler syndrome

Genome editing technology: CRISPR-Cas9, LEAPER (RNA Editing)

Funding stage: Private

Location: Beijing, China


Pipeline: ​​​​

Partnerships: Arbor Biotechnologies, Neukio Biotherapeutics, Immunochina

EdiGene is a clinical-stage, gene-editing company, mainly focused on the development of novel therapies for haematopoietic diseases and cancer. The company holds licenses on proprietary CRISPR-Cas and RNA-editing platforms. The company's most advanced programme is ET-01 which has entered Phase I clinical development. This therapy is developed for the treatment of beta-thalassemia, and thus, is competing with similar programmes from CRISPR Therapeutics/Vertex Pharmaceuticals and Graphite Bio. The company is also developing next-generation CAR-T cell therapies, and these are still at pre-clinical stage.


HashtagEdiGene, Inc.

Company: EdiGene
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine